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Case Report
Mesenteric Fibromatosis Causing Ureteral Stenosis
Jae Young Choi, Kyung Mo Kang, Bum Soo Kim, Tae-Hwan Kim
Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea
Mesenteric fibromatosis is a rare benign disease characterized by proliferating fibrous 
tissue in the bowel mesentery. We report a case of aggressive mesenteric fibromatosis 
with ureteral stenosis arising in a 46-year-old woman who suffered from intermittent 
right abdominal pain. Computed tomography revealed a right retroperitoneal mass 
with right ureteral stenosis at the level of the right common iliac vessel. The mass was 
excised with resection of the affected segment of the ileum, ascending colon, and ureter, 
and end-to-end ureter anastomosis was performed. Pathological examination con-
firmed mesenteric fibromatosis.
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Mesenteric fibromatosis (MF) is a rare, benign, intra-ab-
dominal tumor. MF is characterized by proliferating fi-
brous tissue in the bowel mesentery. Although MF occa-
sionally invades the bowel or adjacent tissues with ag-
gressive myofibroblastic proliferation, MF lacks the ca-
pacity of malignant tumorigenesis with distant metastasis 
[1]. MF is frequently associated with Gardner’s syndrome, 
previous trauma, prolonged estrogen intake, and preg-
nancy, but MF can occur as a primary condition in the ab-
sence of predisposing factors [2]. MF-induced ureteral 
stenosis is a very rare urological problem. We present a case 
of primary MF causing ureteral stenosis with a review of 
the relevant literature.
CASE REPORT
A 46-year-old woman presented with intermittent right 
flank pain she had experienced for a year. The patient had 
previously been healthy and had no history of disease. 
Physical examination revealed no significant findings 
such as tenderness at the costovertebral angle area, a pal-
pable mass, or peripheral lymphadenopathy. Urinalysis, 
a complete blood count, and routine blood biochemistry 
tests showed no abnormal findings. Plain abdominal radio-
graphs were normal. There were no abnormal findings in 
urine cytology or cystoscopic examination. Computed to-
mography (CT) showed a 2.7x1.5 cm diffuse, noncalcified, 
moderately infiltrating mass with ill-defined lobulated 
walls located at the right common iliac vessel level (Fig. 1). 
The mass was located in the right ureter anteriorly, and 
mild focal enhancement, wall thickening, and luminal nar-
rowing were found in the ureter (Fig. 1). The mass looked 
as if it compressed the right ureter, resulting in moderate 
hydroureteronephrosis above the affected level (Fig. 1). 
Retroperitoneal lymphadenopathy was not observed. 
　In a ureterorenoscopic examination, there was no in-
trinsic obstructive lesion such as a ureteral tumor causing 
ipsilateral hydronephrosis. A laparoscopic exploration 
was undertaken to debulk the tumor due to the patient’s 
increasing symptoms. At the time of surgery, due to ex-
tensive adhesion of the ileocecal valve area and mass, the 
laparoscopic exploration was converted to open surgery to 
safely perform the tumor resection. We could not rule out 
the possibility of a malignant tumor before final histo-
pathological confirmation of the affected lesion. The pa-
tient underwent extensive debulking of the mass including 
bowel segmentectomy with anastomosis and excision of the 
affected ureter. Then, end-to-end ureter anastomosis was 
performed, and a ureteral stent was deployed in the right 
urinary tract for decompression. A white wedge of tissue 
was obtained for pathological evaluation.
　The specimen except of resected bowel segment was a 
5.5x3x3 cm firm, poorly circumscribed mass. Upon section-
ing, the cut surface of the mass revealed a white, whorled 
fibrous and trabecular appearance and ill-defined margins 
with the surrounding fat tissue (Fig. 2). Microscopically, Korean J Urol 2010;51:501-504
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FIG. 1. Preoperative computed tomo-
graphy imaging. The contrast-enhanced
coronal reformatted image depicts 
moderate enhancing fibrous tissue 
(arrow 2) with right ureteral stenosis 
(arrow 1).
FIG. 2. Histopathological findings. (A) 
Grossly, the excised mass was ill-defined
and adhered to the small and large in-
testine (ileocecal valve). (B) Excised 
ureteral mass. (C) Mesenteric fibro-
matosis showing cytologically bland 
spindle cells in a collagenous stroma 
(H&E, x200). (D) The cells showed posi-
tive nuclear staining for beta-catenin 
(Immunohistochemical staining, x200).
the lesion was poorly circumscribed, with infiltration of the 
surrounding fat tissue, and was composed of cytologically 
bland, elongated, slender, spindle-shaped cells with collag-
enous stroma containing vessels of varying size. The cells 
were arranged in sweeping bundles and were admixed with 
a storiform growth pattern (Fig. 2). The cells lacked cyto-
logic atypia or nuclear hyperchromasia and had vesicular 
nuclei with minute nucleoli. The mitotic figure was rare. 
In immunohistochemical staining, the spindle- shaped 
cells revealed nuclear β-catenin staining and focally pos-
itive staining for smooth muscle actin (SMA). However, the 
spindle-shaped cells were negative for C-kit (CD117), 
CD34, desmin, and S-100. Given the histopathological 
findings, a diagnosis of mesenteric fibromatosis was con-
firmed (Fig. 2).
　The patient was discharged 5 days after surgery without Korean J Urol 2010;51:501-504
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any complications. The patient is attending follow-ups and 
shows no signs of abnormality or recurrence.
DISCUSSION
Fibromatosis can affect both superficial and deep parts of 
the body. Superficial fibromatosis can involve the face, neck, 
palms, feet, penis, shoulder, thigh, buttocks, or trunk. The 
deep variant can involve the abdominal wall, mesentery, 
retroperitoneum, mediastinum, or abdominal cavity. MF 
is an uncommon variant of deep fibromatosis and has only 
occasionally been reported [3]. Deep (or aggressive) fibro-
matosis is sometimes referred to as a desmoid tumor. A des-
moid tumor is a very rare tumor that may or may not be 
part of a hereditary disease such as familial adenomatous 
polyposis. MF is a rare subtype involving the bowel mesen-
tery (especially that of the small bowel) or retroperitoneum 
and comprises only 8% of all desmoid tumors [4]. Less com-
mon locations are the mesocolon and omentum [2]. The ex-
act etiology of these lesions remains elusive. Various fac-
tors have been implicated by different researchers. Trauma, 
including previous surgery and estrogen exposure, may 
contribute to the formation of these tumors [5]. Genetic pre-
disposition also plays a role, and patients with Gardner’s 
syndrome have a much higher incidence of intra-abdomi-
nal fibromatosis. Although one-third of patients with 
Gardner’s syndrome will have a desmoid tumor, only 2% 
of patients presenting with a desmoid tumor will be found 
to have Gardner’s syndrome [6]. An infectious etiology is 
suggested by an association between human herpes virus 
and retroperitoneal fibromatosis in macaque monkeys [5]. 
The present case is peculiar in that MF presented in a wom-
an without any of these factors.
　Most patients are clinically asymptomatic, with little or 
no focal symptoms until later in the course of the disease, 
at which time they complain of pain, discomfort, con-
stipation, vomiting, abdominal mass, weight loss, and 
symptoms due to organ compression [4]. Some complica-
tions that have been reported include small bowel ob-
struction and hydronephrosis [4]. In our case, the patient 
had intermittent right abdominal pain for a year, but there 
were no other symptoms, such as weight loss, emesis or a 
palpable mass.
　Radiologically, metastatic carcinoma, abdominal lym-
phoma, intestinal carcinoids, peritoneal neoplasms, post-
operative adhesions and retractile mesenteritis form the 
differential diagnoses [3]. A combination of CT for primary 
diagnosis and image-guided biopsies and magnetic reso-
nance imaging (MRI) for periodic follow-up would be rec-
ommended in such patients, as both modalities have a large 
field of view and multiplanar and vascular imaging capa-
bilities. Typical pathological features of MF include a well- 
circumscribed mass, often firmly attached to the small 
bowel; less often MF presents as an ill-defined and irregu-
lar mass. One study reported that the cut surface was a glis-
tening pinkish-white in color and whorled. Histology re-
vealed well-differentiated fibroblasts of uniform size with 
no evidence of mitotic activity, although there was infiltra-
tion of the surrounding tissue. Inflammatory infiltration 
was notably absent [3]. The pathologic confirmation of our 
case and the typical features of MF did not differ. 
　In confirming the pathologic diagnosis of MF, it can be 
difficult to distinguish MF from sclerosing mesenteritis 
that appears to be related to mesenteric panniculitis and 
mesenteric lipodystrophy. In such a case, immunohisto-
chemical staining for beta-catenin can be useful, since MF 
consistently shows strong nuclear beta-catenin staining, 
whereas sclerosing mesenteritis does not express this anti-
gen [7]. Distinguishing MF from gastrointestinal stromal 
tumors (GIST) of the mesentery is also of clinical sig-
nificance due to their vastly different therapeutic and prog-
nostic implications. Although the histopathologic features 
of MF and GIST can sometimes be confused, a differential 
diagnosis between MF and GIST can be carried out using 
immunohistochemical staining. In some studies, CD34 
was common in GIST but was not detected in MF, and MF 
was consistently negative for KIT (CD117), whereas GIST 
was commonly positive. Nuclear beta-catenin staining 
characteristic of MF (but absent in GIST) is also a useful 
finding [7]. SMA, Desmin, and S-100 were not useful for dis-
tinguishing MF from GIST or sclerosing mesenteritis in 
previous studies [7].
　Surgical excision remains the mainstay of MF therapy, 
with non-surgical modalities assuming a secondary role as 
high recurrence rates have been reported when surgery is 
used alone [5]. Indeed, it has been suggested that a re-
currence could be caused by the surgical trauma itself. 
From the literature, it is evident that no single method of 
treatment is effective. The high recurrence rates after sur-
gical excision may reflect the diffuse infiltrative growth 
pattern of desmoid tumors. As many mesenteric fibroma-
toses are unresectable because of their location and extent 
and because they are a cause of morbidity at the same time, 
alternative modes of therapy frequently become the pri-
mary treatment, to be followed by surgery if the tumor 
shrinks to within the limits of resection. Non-surgical mo-
dalities have also been used to reduce the recurrence rate. 
The use of hormonal therapy (i.e., tamoxifen), nonsteroidal 
anti-inflammatory drugs, and interferon as well as sys-
temic chemotherapy may play an important role in the treat-
ment of MF [8]. Post-operative radiation therapy is recom-
mended and is often used for positive margins identified 
histologically, but its role is controversial [5]. In stable tu-
mors and in those that diminish in size, no treatment may 
be necessary. Prognosis is good after complete excision. 
Local recurrences must also be treated by excision. A re-
sidual tumor left behind after surgery takes several years 
to spread before a second exploration is warranted. 
Subsequent surgery, however, is difficult due to extensive 
intraperitoneal adhesions created by previous surgical 
procedures. With each subsequent surgery, morbidity and 
mortality increase [3]. Extensive involvement of the ab-
dominal viscera is the ultimate cause of death after several 
years [3]. Korean J Urol 2010;51:501-504
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　Bilateral ureteral compression by multiple abdominal 
desmoid tumors in Gardner’s syndrome has been described 
[9]. That case was managed by placement of a percutaneous 
nephrostomy tube and surgical removal of the desmoid 
tumors. Ng et al reported another case of hydronephrosis 
in mesenteric fibromatosis with Gardner’s syndrome that 
was treated successfully with a cyclooxygenase-2 inhibitor 
[10]. In our case, the patient was treated by surgical ex-
cision of the mass, and she has been free of the tumor for 
2 months. 
　MF and MF-induced ureteral stenosis is very rare. 
Although many mesenteric fibromatoses can be un-
resectable, patients with MF can undergo treatment suc-
cessfully if we have an appropriate management plan in-
cluding surgery and medical therapy.
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